| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 361,600 | 221,600 | 89,800 | 362,600 |
| Depreciation | 122,200 | 79,900 | 39,100 | 112,000 |
| Amortization | 2,200 | 1,500 | 900 | 2,700 |
| Stock-based compensation | 17,100 | 8,700 | 1,300 | 14,400 |
| Loss on disposal of plant | - | - | - | 0 |
| Non-cash restructuring charges | 2,500 | 1,600 | 800 | - |
| Asset impairments | 4,400 | 4,100 | 300 | 1,900 |
| Other non-cash items, net | 4,400 | 6,900 | 2,900 | 9,700 |
| Changes in assets and liabilities | 1,900 | 4,000 | -100 | 20,600 |
| Net cash provided by operating activities | 503,700 | 306,500 | 129,400 | 463,300 |
| Capital expenditures | 209,800 | 146,500 | 71,300 | 272,100 |
| Other, net | 0 | 0 | - | 1,800 |
| Net cash used in investing activities | -209,800 | -146,500 | -71,300 | -273,900 |
| Borrowings of long-term debt | 0 | 0 | - | 164,700 |
| Repayments of long-term debt | 0 | 0 | 0 | 169,000 |
| Principal repayments on finance leases | 800 | 500 | 200 | 23,200 |
| Excise tax payments | 4,200 | 4,200 | - | - |
| Dividend payments | 45,400 | 30,300 | 15,200 | 43,800 |
| Proceeds from stock-based compensation awards | 8,200 | 6,000 | 2,500 | 24,000 |
| Employee stock purchase plan contributions | 5,400 | 3,600 | 1,900 | 5,600 |
| Shares purchased under share repurchase programs | 134,000 | 134,000 | 133,500 | 506,500 |
| Shares repurchased for employee tax withholdings | 2,600 | 2,500 | 2,500 | 5,500 |
| Net cash used in financing activities | -173,400 | -161,900 | -147,000 | -553,700 |
| Effect of exchange rates on cash | 23,400 | 27,000 | 8,500 | 1,300 |
| Net increase (decrease) in cash and cash equivalents | 143,900 | 25,100 | -80,400 | -363,000 |
| Cash and cash equivalents at beginning of period | 484,600 | 484,600 | 484,600 | 853,900 |
| Cash and cash equivalents at end of period | 628,500 | 509,700 | 404,200 | 490,900 |
WEST PHARMACEUTICAL SERVICES INC (WST)
WEST PHARMACEUTICAL SERVICES INC (WST)